Gradient Denervation Technologies

Executive Summary

Gradient Denervation Technologies is pioneering the Gradient™ Denervation System, a minimally invasive ultrasound-based catheter therapy for pulmonary hypertension (PH), specifically targeting Group 2 PH caused by left-sided heart disease. This condition affects millions worldwide and has limited treatment options beyond managing underlying heart failure. The device aims to modulate the pulmonary artery baroreceptors, reducing sympathetic overactivity and thereby lowering pulmonary pressure. Early feasibility studies have shown promising safety and hemodynamic improvements, positioning Gradient as a potential first-in-class intervention for this large underserved population. The company, based in Paris and founded in 2015, has advanced its platform through preclinical and early clinical work. While still private and pre-revenue, Gradient has likely attracted interest from strategic cardiovascular players due to the high unmet need and novel mechanism. The next 12-18 months are critical as the company moves toward pivotal studies and seeks regulatory designations. Success could transform the PH treatment paradigm, but execution risks remain given the early stage and competitive landscape.

Upcoming Catalysts (preview)

• Q2 2026Pivotal Trial Enrollment Initiation75% success
• Q4 2025FDA Breakthrough Device Designation60% success
• Q1 2026Early Feasibility Study Results Publication90% success